Literature DB >> 26476500

Sutureless aortic valve replacement may improve early mortality compared with transcatheter aortic valve implantation: A meta-analysis of comparative studies.

Hisato Takagi1, Takuya Umemoto2.   

Abstract

OBJECTIVES: To determine which improves clinical outcomes more, sutureless (including rapid-deployment) aortic valve replacement (AVR) or transcatheter aortic valve implantation (TAVI), we performed a meta-analysis of comparative studies.
METHODS: MEDLINE and EMBASE were searched through June 2015 using Web-based search engines (PubMed and OVID). Studies considered for inclusion met the following criteria: the design was a comparative study; the study population included patients with severe aortic valve stenosis, patients were assigned to sutureless AVR versus TAVI; and main outcomes included at least early (in-hospital or 30-day) all-cause mortality.
RESULTS: Of 87 potentially relevant articles screened initially, no randomized controlled trials and 7 observational comparative studies of sutureless AVR versus TAVI (enrolling a total of 945 patients) were identified and included. The first pooled analysis demonstrated a statistically significant reduction in mortality with sutureless AVR over TAVI [2.5% versus 7.3%; odds ratio (OR), 0.33; 95% confidence interval (CI), 0.16 to 0.69; p=0.003; risk difference (RD), -5.23%; 95% CI, -8.12% to -2.33%; p=0.0004]. The second pooled analyses demonstrated no statistically significant difference in bleeding complications, acute kidney injury, and conduction disturbance between sutureless AVR and TAVI. The third pooled analysis demonstrated a statistically significant reduction in paravalvular aortic regurgitation (AR) with sutureless AVR over TAVI (3.5% versus 33.2%; OR, 0.09; 95% CI, 0.05 to 0.16, p<0.00001; MD, -22.56%; 95% CI, -36.59% to -8.53%; p=0.002).
CONCLUSIONS: Compared with TAVI, sutureless AVR may be associated with a reduction in early mortality and postoperative paravalvular AR.
Copyright © 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Meta-analysis; Sutureless aortic valve replacement; Transcatheter aortic valve replacement

Mesh:

Year:  2015        PMID: 26476500     DOI: 10.1016/j.jjcc.2015.09.009

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  6 in total

1.  Transcatheter aortic valve implantation (TAVI) versus sutureless aortic valve replacement (SUAVR) for aortic stenosis: a systematic review and meta-analysis of matched studies.

Authors:  Nelson Wang; Yi-Chin Tsai; Natasha Niles; Vakhtang Tchantchaleishvili; Marco Di Eusanio; Tristan D Yan; Kevin Phan
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

2.  Cost-utility of surgical sutureless bioprostheses vs TAVI in aortic valve replacement for patients at intermediate and high surgical risk.

Authors:  Massimiliano Povero; Antonio Miceli; Lorenzo Pradelli; Matteo Ferrarini; Matteo Pinciroli; Mattia Glauber
Journal:  Clinicoecon Outcomes Res       Date:  2018-11-08

Review 3.  Recent advances in aortic valve replacement.

Authors:  Cristiano Spadaccio; Khalid Alkhamees; Nawwar Al-Attar
Journal:  F1000Res       Date:  2019-07-22

4.  Perceval S, sutureless aortic valve: cost-consequence analysis.

Authors:  Ioannis Panagiotopoulos; Nikolaos Kotsopoulos; Georgios-Ioannis Verras; Francesk Mulita; Anastasia Katinioti; Efstratios Koletsis; Konstantinos Triantafyllou; John Yfantopoulos
Journal:  Kardiochir Torakochirurgia Pol       Date:  2022-03-24

5.  Non-Inferiority of Sutureless Aortic Valve Replacement in the TAVR Era: David versus Goliath.

Authors:  Alina Zubarevich; Marcin Szczechowicz; Lukman Amanov; Arian Arjomandi Rad; Anja Osswald; Saeed Torabi; Arjang Ruhparwar; Alexander Weymann
Journal:  Life (Basel)       Date:  2022-06-29

6.  Valve-in-Valve Replacement Using a Sutureless Aortic Valve.

Authors:  Pascal M Dohmen; Lukas Lehmkuhl; Michael A Borger; Martin Misfeld; Friedrich W Mohr
Journal:  Am J Case Rep       Date:  2016-10-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.